Page last updated: 2024-11-12
rs 20
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
RS 20: 16 amino acid residues given in first source; derived from the calmodulin-binding domain of MLCK binds calmodulin with high affinity; potent inhibitor of MLCK activity; inhibits contraction of skinned smooth muscle as well as phosphorylation of myosin light chains [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 16131017 |
MeSH ID | M0169685 |
Synonyms (6)
Synonym |
---|
rs 20 |
120396-89-6 |
rs-20 |
l-alanyl-l-arginyl-l-arginyl-l-lysyl-l-tryptophyl-l-glutaminyl-l-lysyl-l-threonylglycyl-l-histidyl-l-alanyl-l-valyl-l-arginyl-l-alanyl-l-isoleucylglycyl-l-arginyl-l-leucyl-l-seryl-l-serine |
l-serine, l-alanyl-l-arginyl-l-arginyl-l-lysyl-l-tryptophyl-l-glutaminyl-l-lysyl-l-threonylglycyl-l-histidyl-l-alanyl-l-valyl-l-arginyl-l-alanyl-l-isoleucylglycyl-l-arginyl-l-leucyl-l-seryl- |
DTXSID80152839 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (8)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 1 (12.50) | 18.7374 |
1990's | 5 (62.50) | 18.2507 |
2000's | 2 (25.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 69.70
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (69.70) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 8 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |